Last $6.71 USD
Change Today +0.08 / 1.21%
Volume 110.4K
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Open
$6.65
Previous Close
$6.63
Day High
$6.80
Day Low
$6.53
52 Week High
01/15/14 - $11.00
52 Week Low
07/31/14 - $5.80
Market Cap
297.2M
Average Volume 10 Days
59.7K
EPS TTM
$0.14
Shares Outstanding
44.3M
EX-Date
--
P/E TM
47.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUCAMPO PHARMACEUTICALS-CL A (SCMP)

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. It is developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its collaboration and license agreement with Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; and opioid-induced constipation in adults with chronic non-cancer pain. It also provides AMITIZA in Japan through its collaboration and license agreement with Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, the company markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. Its pipeline also includes AMITIZA, which is in Phase III trial for pediatric functional constipation. The company’s other pipeline products consist of IV Ion Channel Activator, which is in Phase IIa clinical trial for the treatment of Lumbar spinal stenosis; PO Ion Channel Activator that is in Phase Ia trial for the treatment of Lumbar spinal stenosis; and cobiprostone, which has completed Phase I clinical development for the treatment of oral mucositis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

77 Employees
Last Reported Date: 03/12/14
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $593.5K
Chief Financial Officer
Total Annual Compensation: $336.0K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $338.9K
Principal Accounting Officer
Total Annual Compensation: $273.9K
Compensation as of Fiscal Year 2013.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Full Year 2014

Sucampo Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues were $24,069,000 against $27,023,000 a year ago. Income from operations was $3,811,000 against $10,169,000 a year ago. Income before income taxes was $3,389,000 against $10,569,000 a year ago. Net income was $1,610,000 or $0.04 per basic and diluted share against $6,245,000 or $0.15 per basic and diluted share a year ago. Capital expenditures were $8,000 against $8,000 a year ago. For the six months, total revenues were $46,230,000 against $43,942,000 a year ago. Income from operations was $6,540,000 against $7,561,000 a year ago. Income before income taxes was $5,452,000 against $8,635,000 a year ago. Net income was $2,366,000 or $0.05 per basic and diluted share against $3,169,000 or $0.07 per diluted share a year ago. The decrease of net income for both periods was driven by the receipt in 2013 of a $10.0 million milestone payment from Takeda upon the first commercial sale of AMITIZA for OIC. Capital expenditures were $49,000 against $140,000 a year ago. The company increased its earnings guidance for 2014. They now expect full year 2014 GAAP net income to be in the range of $4.0 million to $6.0 million, or $0.08 to $0.13 per diluted share.

Sucampo Pharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 05, 2014

Sucampo Pharmaceuticals, Inc. announced that they will report Q2, 2014 results Pre-Market on Aug 05, 2014

Sucampo Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 05, 2014

Sucampo Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $6.71 USD +0.08

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $5.08 USD +0.05
Momenta Pharmaceuticals Inc $11.52 USD -0.08
Pernix Therapeutics Holdings Inc $7.47 USD -0.10
Progenics Pharmaceuticals Inc $5.08 USD -0.14
Sagent Pharmaceuticals Inc $30.90 USD +0.04
View Industry Companies
 

Industry Analysis

SCMP

Industry Average

Valuation SCMP Industry Range
Price/Earnings 51.4x
Price/Sales 3.2x
Price/Book 4.2x
Price/Cash Flow 52.9x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit www.sucampo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.